Coronil gets Ayush Ministry certification as 'supporting measure' for COVID-19 treatment

The medicine was launched at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

February 19, 2021 01:17 pm | Updated 01:35 pm IST - New Delhi

A photo of the kit released by Patanjali on Twitter.

A photo of the kit released by Patanjali on Twitter.

Haridwar-based Patanjali Ayurved on Friday said Coronil has now received certification from Ayush Ministry as per World Health Organization (WHO) certification scheme.

The company claimed that it is the first evidence-based medicine to fight COVID-19.

The medicine was launched here at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

"Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme," said Patanjali in a statement.

Under CoPP, Coronil can now be exported to 158 countries.

Commenting of the development Swami Ramdev said, Coronil will help the humanity while providing affordable treatment based on naturopathy.

On the basis of presented data, the Ministry of Ayush has recognised Coronil Tablet as a medicine for "supporting measure in COVID-19." Patanjali had earlier introduced Ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak.

However, it had to face severe criticism as it lacked scientific evidence.

Then, the Ayush Ministry had indicated it as "Immuno-booster" only.

Coronil is developed by Patanjali Research Institute. It had started work for an Ayurvedic remedy for COVID-19 in January, 2020.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.